JB Pharma Q1 Results: Net profit surges 35% YoY to Rs 142 crore

JB Pharma on Wednesday said its net profit rose 35% year-on-year (YoY) to Rs 142 crore for the first quarter ended June 30, 2023, led by strong momentum of its chronic portfolio and acquired assets.

The PE firm KKR-backed company had reported net Rs 105 crore in the April-June quarter of FY23.

Revenue grew 14% YoY to Rs 896 crore in Q1FY24 Operating earnings before interest, depreciation and tax increased by 28% to Rs 243 crores. EBITDA margins expanded 290 basis on YoY to 27.1%.


Domestic business revenue grew 17% YoY to Rs 489 crores in Q1FY24, despite sales for the acute business being impacted due to the delayed monsoons.

The company said all its four acquisitions - the probiotic portfolio, Paedia brands, Azmarda and Razel have performed well.

As per data analytics firm IQVIA - JB Pharma is ranked amongst the top 25 in India. Its top selling brands heartburn brand Rantac, anti-hypertensive medications Cilacar, Cilacar-T and Nicardia and anti-parasitic drug Metrogyl have all improved ranks during Q1FY24.

International Business recorded 11% YoY growth to Rs 407 crores.

“Our domestic business continued its growth trajectory through strong
momentum in our chronic portfolio and acquired assets. Our big brands, especially in the chronic segment, continue to outpace the market," said Nikhil Chopra, CEO and wholetime director, JB Pharma.

"EBITDA margins improved during the quarter on account of better business mix, increased efficiencies in sourcing, and higher volumes..we will maintain our distinctive focus on India and the CDMO business, while maintaining our efforts to control costs and increase efficiencies across the organisation,” Chopra added.